A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Colorectal Neoplasms Clinical Trial

Official title:

An Open-label Phase 1 Study of E7386 in Subjects With Advanced Solid Tumor Including Colorectal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03833700
• Other study ID #: E7386-J081-103
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 5, 2019
• Est. completion date: March 31, 2025

Study information

• Verified date: November 2023
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

Description:

The study will be conducted in 3 parts: dose escalation part, expansion part 1 and expansion part 2. The study will include Pre-treatment Phase, Treatment Phase, and Extension Phase (in expansion parts only).

Eligible participants from Pre-Treatment Phase (screening period) will enter into the Treatment Phase to receive E7386. After Treatment Phase, participants will be followed in follow-up period of Extension Phase (in expansion parts only).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 70
• Est. completion date: March 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants with a histological and/or cytological diagnosis of solid tumor must have any of the following tumor types:

1. Dose Escalation Part: Participants with advanced, unresectable, or recurrent solid tumor including CRC for which no alternative standard therapy or no effective therapy exists

2. Expansion Part 1: Participants with advanced, unresectable, or recurrent CRC in third- or later-line, Or participants with other gastrointestinal tumors such as small bowel carcinoma and gastrointestinal neuroendocrine tumors after at least 1 prior systemic chemotherapy regimen upon discussion and agreement with the sponsor

3. Expansion Part 2: Participants with advanced, unresectable, or recurrent solid tumors expected to be highly dependent on wingless/integrated (Wnt)/ß-catenin signaling pathway as specified below, who have no standard therapy. Disease progression must be confirmed within the past 12 months.

• Desmoid tumor

• Solid pseudopapillary neoplasm (SPN) of pancreas

• Small bowel carcinoma with mutation of catenin beta-1 (CTNNB1) or adenomatous polyposis coli (APC)

• Adrenocortical carcinoma (ACC) with mutation of CTNNB1, APC or zinc and ring finger 3 (ZNRF3)

• Solid tumors (except for CRC) with APC mutation in participants diagnosed as familial adenomatous polyposis (FAP)

• Hepatocellular carcinoma (HCC) with CTNNB1 gain-of-function mutation

• Other types of solid tumors (except for CRC) harboring one or more Wnt-related gene mutations (example, APC, AXIN1, CTNNB1, ring finger protein 43 [RNF43], et cetera) expected to be highly dependent on Wnt/ß-catenin signaling pathway based on emerging data may be enrolled upon consultation and agreement with the sponsor.

HCC participants must have:

1. A diagnosis of HCC that is histologically or cytologically confirmed (excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors) or clinically confirmed according to American Association for the Study of Liver Disease criteria, including cirrhosis of any etiology and/or chronic hepatitis B or C infection.

2. Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach

2. Dose Escalation Part: Participants with CRC must consent to biopsy and submit the archival tumor tissue if it is stored.

Expansion Part 1: Participants with accessible tumors must consent to tumor biopsy. Participants with inaccessible tumors may be enrolled without a biopsy upon consultation and agreement by the sponsor. Participants must consent to submit the archival tumor tissue if it is stored.

Expansion Part 2: Participants must consent to submit the archival tumor tissue if available. Desmoid tumor participants with no results of genetic assays must consent to submit archival tumor tissue or tumor biopsy at screening.

3. Life expectancy of >=12 weeks.

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

5. All AEs due to previous anti-cancer therapy have either returned to Grade 0-1 except for alopecia and Grade 2 peripheral neuropathy (renal/bone marrow/liver function should meet the inclusion criteria).

6. Adequate washout period before study drug administration:

1. Chemotherapy and radiotherapy: 3 weeks or more

2. Any therapy with antibody (Ab): 4 weeks or more

3. Any investigational drug or device: 4 weeks or more

4. Blood/platelet transfusion or Granulocyte-colony stimulating factor (G-CSF): 2 weeks or more

7. Adequate renal, bone marrow, liver function, and serum mineral level.

8. At least one measurable lesion based on RECIST 1.1.

9. Participants must agree to take Vitamin D continuous supplementation as per local institutional guideline/ investigators clinical discretion when 25-hydroxyvitamin D levels less than ng/mL (nanogram per milliliter).

10. Dose escalation part: Participants must consent to skin biopsies from skin tissue that is tumor-free during the study. Expansion part 1: At least 5 participants in each dose level must consent to skin biopsies from skin tissue that is tumor-free during the study. Participants may be enrolled without skin biopsies upon consultation and agreement by the sponsor. Expansion part 2: Participants must consent to skin biopsies from skin tissue that is tumor-free during the study in principle. Participants may be enrolled without consent to skin biopsies upon consultation and agreement by the sponsor.

Exclusion Criteria:

1. Known to be human immunodeficiency virus (HIV) positive.

2. Active infection requiring systemic treatment.

For participants with HCC in Expansion part 2: In case of Hepatitis B surface antigen (HBsA g) positive (+) participants:

1. Antiviral therapy for Hepatitis B virus (HBV) is not ongoing

2. HBV viral load is 2000 International units per milliliter (IU/mL) or more at the Screening Period although antiviral therapy for HBV is ongoing

3. Has dual active HBV infection (HBsAg [+] and/or detectable HBV Deoxyribonucleic acid [DNA]) and Hepatitis C virus (HCV) infection (anti-HCV Ab [+] and detectable HCV Ribonucleic acid [RNA]) at study entry

3. Diagnosed with meningeal carcinomatosis.

4. Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example: radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.

5. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.

6. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (example: nausea, diarrhea, or vomiting) that might impair the bioavailability of E7386.

7. Any of bone disease/conditions as follows;

1. Osteoporosis with T-score less than (<) -3 at the left or right total hip, left or right femoral neck or lumbar spine (L1-L4) as determined by dual energy X-ray absorptiometry (DXA) scan. Participants with T-score <-2.5 to -3.0 and no prior medical therapy for osteoporosis can only be included provided that treatment with a bisphosphonate (example, zoledronic acid) or denosumab has been started at least 14 days prior to the first dose of study drug

2. Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia

3. Symptomatic hypercalcemia requiring bisphosphonate therapy

4. History of any fracture within 6 months prior to starting study drug

5. Any condition requiring orthopedic intervention

6. Bone metastasis, not being treated by bisphosphonate or denosumab. Participant may be included if treatment with bisphosphonate or denosumab have been started at least 14 days prior to the first dose of study drug. Participants with previous solitary bone lesions controlled with radiotherapy are eligible

7. History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less)

8. Moderate (25 percent [%] to 40% decrease in the height of any vertebrae) or severe (more than [>] 40% decrease in the height of any vertebrae) morphometric vertebral fracture at baseline.

8. History of active malignancy (except for original disease, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of the bladder or cervix, or early stage gastric/colorectal cancer) within the past 24 months prior to the first dose of study drug.

9. Prior treatment with E7386.

10. For participants with HCC in Expansion part 2, if the participants have:

1. Child-Pugh status of B and C

2. clear invasion of the HCC to the bile duct

3. symptomatic gastric or esophageal varices per Investigator's clinical judgement

4. history of hepatic encephalopathy within 6 months prior to starting study drug unresponsive to therapy within 3 days. Participants on rifaximin or lactulose during screening to control their hepatic encephalopathy are not allowed

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Gastrointestinal Tumors
• Neoplasms
• Solid Neoplasms

Intervention

Drug:
• E7386
E7386, tablets, orally.

Locations

Country	Name	City	State
Japan	Eisai Trial Site #1	Chuo Ku	Tokyo
Japan	Eisai Trial Site #4	Fukuoka
Japan	Eisai Trial Site #2	Kashiwa	Chiba
Japan	Eisai Trial Site #3	Nagaizumi-cho	Shizuoka
Japan	Eisai Trial Site#7	Nagoya	Aichi
Japan	Eisai Trial Site#6	Osaka
Japan	Eisai Trial Site #5	Sapporo	Hokkaido
Japan	Eisai Trial Site#8	Sendai	Miyagi

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Dose-limiting Toxicities (DLTs)	DLT will be defined as any of the events that are considered by the investigator to be at least possibly related to therapy with the study medication. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).	Baseline up to Cycle 1 (Cycle length is equal to [=] 28 days)
Primary	Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)		Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (approximately 6 years)
Secondary	Cmax: Maximum Observed Plasma Concentration for E7386		Dose Escalation Part: Cycle1 Days1 and 8: 0-12 hours, Cycle2-6 Day1: Pre-dose; Dose Expansion Part 1: Cycle1 Days1 and 8: 0-2 hours, Cycle2 Day1: Pre-dose; Dose Expansion Part 2: Cycle1 Days1 and 8: 0-6 hours, Cycle2 Day1: Pre-dose(Cycle length=28 days)
Secondary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386		Dose Escalation Part: Cycle1 Days1 and 8: 0-12 hours, Cycle2-6 Day1: Pre-dose; Dose Expansion Part 1: Cycle1 Days1 and 8: 0-2 hours, Cycle2 Day1: Pre-dose; Dose Expansion Part 2: Cycle1 Days1 and 8: 0-6 hours, Cycle2 Day1: Pre-dose(Cycle length=28 days)
Secondary	AUC: Area Under the Plasma Concentration Versus Time Curve for E7386		Dose Escalation Part: Cycle1 Days1 and 8: 0-12 hours, Cycle2-6 Day1: Pre-dose; Dose Expansion Part 1: Cycle1 Days1 and 8: 0-2 hours, Cycle2 Day1: Pre-dose; Dose Expansion Part 2: Cycle1 Days1 and 8: 0-6 hours, Cycle2 Day1: Pre-dose(Cycle length=28 days)
Secondary	CL/F: Apparent Total Body Clearance for E7386		Dose Escalation Part: Cycle1 Days1 and 8: 0-12 hours, Cycle2-6 Day1: Pre-dose; Dose Expansion Part 1: Cycle1 Days1 and 8: 0-2 hours, Cycle2 Day1: Pre-dose; Dose Expansion Part 2: Cycle1 Days1 and 8: 0-6 hours, Cycle2 Day1: Pre-dose(Cycle length=28 days)
Secondary	Vz/F: Apparent Volume of Distribution for E7386		Dose Escalation Part: Cycle1 Days1 and 8: 0-12 hours, Cycle2-6 Day1: Pre-dose; Dose Expansion Part 1: Cycle1 Days1 and 8: 0-2 hours, Cycle2 Day1: Pre-dose; Dose Expansion Part 2: Cycle1 Days1 and 8: 0-6 hours, Cycle2 Day1: Pre-dose(Cycle length=28 days)
Secondary	Percentage of Participants with Best Overall Response (BOR)	BOR is defined as complete response (CR), partial response (PR), stable disease (SD), PD, and not evaluable (NE), where SD has to be achieved at greater than or equal to (>=) 7 weeks after the first dose. The BOR will be assessed by investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)
Secondary	Objective Response Rate (ORR)	The ORR is defined as the percentage of participants with a BOR of CR or PR. The ORR will be assessed by investigator based on RECIST version 1.1.	From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)
Secondary	Disease Control Rate (DCR)	DCR is defined as the percentage of participants with a BOR of CR, PR, or SD. The DCR will be assessed by investigator based on RECIST version 1.1.	From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)
Secondary	Clinical Benefit Rate (CBR)	The CBR is defined as the percentage of participants with a BOR of CR, PR, or durable SD (duration of SD >=23 weeks). The CBR will be assessed by investigator based on RECIST version 1.1.	From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)
Secondary	Progression-free Survival (PFS)	PFS is defined as the time from the date of the first dose to the date of the first documentation of confirmed PD or death, whichever occurs first.	From first dose of study drug until PD, or death from any cause, whichever occurs first (up to approximately 6 years)
Secondary	Duration of Response (DOR)	DOR is defined as the time from the first date of documented CR or PR to the date of PD or death, whichever occurs first. It will be calculated for participants whose BOR is CR or PR. DOR will be assessed according to RECIST version 1.1.	From the date of first documented CR or PR until first documentation of PD or death (up to approximately 6 years)
Secondary	Overall Survival (OS)	OS is defined as the time from the date of first dose to the date of death.	From first dose of study drug until date of death (up to approximately 6 years)